BEHRENS M KATHLEEN 4
4 · Sarepta Therapeutics, Inc. · Filed Jun 5, 2026
Research Summary
AI-generated summary of this filing
Sarepta (SRPT) Director Kathleen M. Behrens Receives RSU Award
What Happened
Kathleen M. Behrens, a director of Sarepta Therapeutics (SRPT), was granted 16,875 restricted stock units (RSUs) on 2026-06-04. Each RSU represents the right to receive one share of Sarepta common stock upon vesting. No per-share price or immediate cash value was reported (price = N/A); this is a grant/award (transaction code A), not an open-market buy or sale.
Key Details
- Transaction date: 2026-06-04 (Form 4 filed 2026-06-05 — timely filing).
- Grant: 16,875 RSUs; price reported as N/A (typical for awards).
- Vesting: RSUs vest on the earlier of the one-year anniversary of grant or the next annual meeting of stockholders that is at least 50 weeks after the prior meeting (per footnote).
- Shares owned after transaction: not specified in the Form 4 filing.
- Transaction type: Award/Grant (A); not a purchase or sale and not an exercise.
Context
RSUs are a common form of director compensation and convert to shares only after vesting; they are not immediately tradable and do not necessarily indicate the director is buying or selling stock. This grant is routine equity compensation rather than an express market sentiment signal.
Insider Transaction Report
- Award
Common Stock
[F1]2026-06-04+16,875→ 214,357 total
- 10,000(indirect: By Trust)
Common Stock
Footnotes (1)
- [F1]The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting.